Latest Conference Articles

There are several live microbiota therapeutics in development, including RBX2660.

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.

A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.

The NIDA director reviews neuromodulation's potential role in treating patients with multiple use disorders, and the importance of patient feedback in shaping clinical research.

Rachel Talley, MD, discusses the industry-level changes needed to trainee recruitment and retention to create a psychiatry field more representative of its patient population.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

The age of screening for colon cancer has decreased in recent years.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively

The treatment recently became the first ever FDA-approved medication for EoE.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.

The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.

Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

The lead author of treatment recommendations weighs in on their current use and future research.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Patients with IBD are often at an increased risk of developing NAFLD.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.

Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.

Amid significant psychotherapy innovation and consideration to broader aspects of mental illness definition, Jonathan Alpert, MD, PhD, emphasizes the need for improved clinical trial standards.

Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.